Rosilio, C
Nebout, M
Imbert, V
Griessinger, E
Neffati, Z
Benadiba, J
Hagenbeek, T
Spits, H
Reverso, J
Ambrosetti, D
Michiels, J-F
Bailly-Maitre, B
Endou, H
Wempe, M F
Peyron, J-F
Article History
Received: 30 April 2014
Revised: 25 October 2014
Accepted: 30 October 2014
First Online: 8 December 2014
Competing interests
: HE is CEO of J-Pharma Co., Ltd. (Yokohama, Japan) while MFW served as a Scientific Advisory Board Member for J-Pharma from August 2006 to July 2013. J-Pharma has been developing LAT1 inhibitor JPH203 for use regarding cancer therapeutics/diagnostics; consequently, HE and MFW have a financial interest in J-Pharma. The remaining authors declare no conflict of interest.